Data updated: Jun 28, 2026
Diabetic Complications Clinical Trial Landscape
Diabetic Complications is being studied across 611 clinical trials registered since 2008, with 106 programs currently active. The competitive pipeline includes 25 active Phase 3 trials, 44 active Phase 2 trials, and 16 active Phase 1 trials.
Top industry sponsors include Roche, EyeBiotech Ltd., Regeneron.
Trial activity
106 active / 611 total since 2008
Active by phase 25 Ph3 / 138 44 Ph2 / 269 16 Ph1 / 70 21 Ph4 / 134
Sponsor activity
Who is running trials now — green active, blue completed, red failed/terminated.
Sorted by active Active Done Failed
Roche 5 12 0
EyeBiotech Ltd. 3 1 0
Regeneron 2 7 0
AbbVie 2 2 2
Boehringer Ingelheim 2 3 0
EyePoint Pharmaceuticals, Inc. 2 3 0
Frontera Therapeutics 2 0 0
Novartis 1 22 5
Alimera Sciences 1 3 0
Curacle Co., Ltd. 1 2 0
Outlook Therapeutics, Inc. 1 1 0
Bio-Thera Solutions 1 1 0
Kyowa Kirin Co., Ltd. 1 0 1
Ashvattha Therapeutics, Inc. 1 1 0
RemeGen Co., Ltd. 1 1 0
How the field has grown
New-trial starts peaked in 2024 (38 registered); 2025 saw 25. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (79 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.
New trials started by year
2016 32
2017 25
2018 35
2019 28
2020 37
2021 35
2022 31
2023 27
2024 38
2025 25
2026 27
TheraRadar.com
Median Phase 3 enrollment by start year
2016 (9) 205
2017 (4) 122
2018 (11) 355
2019 (5) 266
2020 (11) 195
2021 (10) 187
2022 (5) 46
2023 (1) 316
2024 (13) 333
2025 (4) 678
2026 (6) 240
TheraRadar.com
Full trial pipeline
Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.
NCT07449936 RECRUITING
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
EyePoint Pharmaceuticals, Inc. n=240
NCT07449923 RECRUITING
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
EyePoint Pharmaceuticals, Inc. n=240
NCT07489131 RECRUITING
Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema
Alvotech Swiss AG n=256
NCT05112861 ACTIVE NOT RECRUITING
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
Outlook Therapeutics, Inc. n=120
NCT07515079 RECRUITING
Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema
Bio-Thera Solutions n=406
NCT07235085 RECRUITING
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
Ocular Therapeutix, Inc. n=930
NCT04108156 ACTIVE NOT RECRUITING
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
Hoffmann-La Roche n=634
NCT06790784 RECRUITING
Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
Jaeb Center for Health Research n=426
NCT01320345 ACTIVE NOT RECRUITING
The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.
University of Sydney n=412
NCT06957080 ACTIVE NOT RECRUITING
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
EyeBiotech Ltd. n=1,054
NCT04661358 RECRUITING
Fenofibrate for Prevention of DR Worsening
Jaeb Center for Health Research n=560
NCT06491914 ACTIVE NOT RECRUITING
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Regeneron Pharmaceuticals n=1,118
NCT06817265 RECRUITING
Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy
Beletalent (Zhuhai) Pharmaceutical Co., Ltd n=360
NCT06571045 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
EyeBiotech Ltd. n=984
NCT06305416 RECRUITING
A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema
Incepta Pharmaceuticals Ltd n=70
NCT06951087 ENROLLING BY INVITATION
Intravitreal and Intracameral DEX in NPDR
Affiliated Hospital of Nantong University n=80
NCT06201611 RECRUITING
Evaluating a Nitric Oxide Generator, Nebivolol as a Disease Modifier in Patients With Diabetic Neuropathy.
St. John's Research Institute n=120
NCT06606093 NOT YET RECRUITING
Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients
Daewoong Pharmaceutical Co. LTD. n=348
NCT06595355 RECRUITING
Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin
Isfahan University of Medical Sciences n=52
NCT06441591 RECRUITING
Clinical Outcome of Vinpocetine in Diabetic Nephropathy
Ain Shams University n=64
NCT06068439 NOT YET RECRUITING
Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic Nephropathy
Second Affiliated Hospital, School of Medicine, Zhejiang University n=355
NCT05885503 RECRUITING
Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema
RemeGen Co., Ltd. n=316
NCT07598864 NOT YET RECRUITING
"Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD With Type 2 Diabetes"
Chittagong Medical College n=88
NCT07592273 RECRUITING
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
AbbVie n=576
NCT06270836 COMPLETED
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
Kodiak Sciences Inc n=255
NCT05066997 COMPLETED
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)
Oculis n=552
NCT06172257 COMPLETED
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)
Oculis n=401
NCT04503551 COMPLETED
A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm
Hoffmann-La Roche n=174
NCT06422507 COMPLETED
A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema
Bayer n=333
NCT05217680 COMPLETED
Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema
Laboratorios Sophia S.A de C.V. n=509
NCT01766362 COMPLETED
Incidence of Macular Edema After Panretinal Photocoagulation (PRPC) Performed in a Single Session Versus Four Sessions in Diabetic Patients.
Centre Hospitalier Universitaire Dijon n=83
NCT04432831 COMPLETED
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema
Hoffmann-La Roche n=1,479
NCT03436693 COMPLETED
Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
Tanabe Pharma Corporation n=308
NCT04278417 COMPLETED
Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
Novartis Pharmaceuticals n=689
NCT04055090 COMPLETED
Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy
Helixmith Co., Ltd. n=101
NCT04469270 COMPLETED
Study to Assess Safety and Efficacy of Engensis in Painful Diabetic Peripheral Neuropathy
Helixmith Co., Ltd. n=162
NCT02427464 COMPLETED
Phase 3 Gene Therapy for Painful Diabetic Neuropathy
Helixmith Co., Ltd. n=507
NCT04429503 COMPLETED
Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
Regeneron Pharmaceuticals n=660
NCT03622580 COMPLETED
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)
Hoffmann-La Roche n=940
NCT03622593 COMPLETED
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema
Hoffmann-La Roche n=951
NCT05989126 COMPLETED
Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
Regeneron Pharmaceuticals n=35
NCT04516278 COMPLETED
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
Outlook Therapeutics, Inc. n=195
NCT03481660 COMPLETED
A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
Novartis Pharmaceuticals n=360
NCT04058067 COMPLETED
To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema
Novartis Pharmaceuticals n=266
NCT05066230 TERMINATED
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)
Kodiak Sciences Inc n=253
NCT04603937 TERMINATED
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
Kodiak Sciences Inc n=459
NCT04611152 TERMINATED
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
Kodiak Sciences Inc n=460
NCT00600301 WITHDRAWN
Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study
Asociación para Evitar la Ceguera en México
NCT05487755 COMPLETED
Investigational and Comparative Study in the Management of Diabetic Nephropathy
Tanta University n=90
NCT03321513 COMPLETED
DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME
Jaeb Center for Health Research n=270
NCT04741074 TERMINATED
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
Geisinger Clinic n=15
NCT03164785 COMPLETED
Efficacy and Safety of Jinshuibao Capsule on Diabetic Kidney Disease
Second Xiangya Hospital of Central South University n=202
NCT04739306 COMPLETED
Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema
Celltrion n=348
NCT06115460 COMPLETED
The Impact of Sitagliptin as an Add on Therapy With Closed Loop Control in Adolescents With Diabetic Nephropathy
Ain Shams University n=46
NCT05569148 COMPLETED
A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe
Hoffmann-La Roche n=35
NCT03784443 WITHDRAWN
Combined Ranibizumab and Iluvien for Diabetic Macular Oedema
Imperial College London
NCT03550443 TERMINATED
A Phase 3 Study of Bardoxolone Methyl in Patients With Diabetic Kidney Disease; AYAME Study
Kyowa Kirin Co., Ltd. n=1,323
NCT02634333 COMPLETED
Anti-VEGF Treatment for Prevention of PDR/DME
Jaeb Center for Health Research n=399
NCT02689778 COMPLETED
Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic Nephropathy
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran n=62
NCT03610646 COMPLETED
Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME)
Mylan Pharmaceuticals Inc n=355
NCT03481634 COMPLETED
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
Novartis Pharmaceuticals n=566
NCT04674800 COMPLETED
Extension Study of MYL-1701P-3001 for Safety and Efficacy
Mylan Pharmaceuticals Inc n=52
NCT03917472 COMPLETED
Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
Novartis Pharmaceuticals n=517
NCT02985619 COMPLETED
Bevacizumabe or Triamcinolone for Persistent Diabetic Macular Edema
University of Sao Paulo n=100
NCT05127525 TERMINATED
EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)
iRenix Medical, Inc. n=5
NCT02545049 COMPLETED
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
Bayer n=7,352
NCT03702374 COMPLETED
Combined Antioxidant Therapy on Oxidative Stress, Mitochondrial Dysfunction Markers in Diabetic Retinopathy
University of Guadalajara n=132
NCT05271539 COMPLETED
Intravitreal Ranibizumab Versus Its Combination With Dexamethasone in The Treatment of Diabetic Macular Edema
Cairo University n=42
NCT03660345 COMPLETED
PPV With Internal Limiting Membrane Peeling for Treatment-Naïve DME
Rush Eye Associates n=11
NCT01489189 COMPLETED
Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Jaeb Center for Health Research n=305
NCT05029297 COMPLETED
Study With Two Capsaicin Topic Treatments in Diabetic Neuropathy.
Arafarma Group, S.A. n=161
NCT04253860 TERMINATED
Effect of Transcutaneous Electrical Nerve Stimulation in Diabetic Neuropathy
Centro Universitario de Tonalá n=20
NCT03478306 COMPLETED
Diabetic Retinopathy: Effects of Melatonin Treatment on Visual Functions and Circadian Rhythm
Glostrup University Hospital, Copenhagen n=31
NCT02858076 COMPLETED
Anti-VEGF vs. Prompt Vitrectomy for VH From PDR
Jaeb Center for Health Research n=205
NCT01572350 COMPLETED
Safety and Efficacy of Triamcinolone Acetonide Combined With Laser, Bevacizumab Combined With Laser Versus Laser Alone for the Treatment of Diffuse Non-tractional Diabetic Macular Edema
Hospital Universitario de Canarias n=105
NCT01332149 COMPLETED
Study To Evaluate Efficacy, Safety And Tolerability Of Lyrica In Patients With Painful Diabetic Peripheral Neuropathy
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. n=626
NCT00553280 COMPLETED
A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. n=123
NCT01057693 COMPLETED
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. n=633
NCT03105219 WITHDRAWN
IvaBradinE to Treat MicroalbumiNuria in Patients With Type 2 Diabetes and Coronary Heart Disease
Nanjing First Hospital, Nanjing Medical University
NCT03345901 TERMINATED
PROMINENT-Eye Ancillary Study (Protocol AD)
Jaeb Center for Health Research n=18
NCT01627249 COMPLETED
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
Jaeb Center for Health Research n=660
NCT02229175 WITHDRAWN
Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema
University of California, San Francisco
NCT01909791 COMPLETED
Treatment for CI-DME in Eyes With Very Good VA Study
Jaeb Center for Health Research n=702
NCT02718326 COMPLETED
Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)
Regeneron Pharmaceuticals n=402
NCT04288232 COMPLETED
Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan
Taipei Veterans General Hospital, Taiwan n=45
NCT03173963 WITHDRAWN
Empaglifozin in Early Diabetic Kidney Disease
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT02065791 COMPLETED
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
Janssen Research & Development, LLC n=4,401
NCT03143192 COMPLETED
Treatment of Diabetic Macular Edema With Aflibercept and Micropulse Laser
Keyvan Koushan n=31
NCT01908816 COMPLETED
An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.
Novartis Pharmaceuticals n=270
NCT02262260 COMPLETED
Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME
Novartis Pharmaceuticals n=87
NCT01661946 COMPLETED
Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye
Queen's University n=10
NCT01847313 COMPLETED
The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease
Karl Neff n=20
NCT02259088 COMPLETED
A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients
Novartis Pharmaceuticals n=384
NCT02157350 COMPLETED
The Individually Marked Panretinal lasEr phoTokoagUlation for Proliferative Diabetic Retinopathy Study - DETECT
Odense University Hospital n=65
NCT02040441 COMPLETED
Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria
Peter Rossing n=1,777
NCT01976923 COMPLETED
Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy
J. Fernando Arevalo, MD FACS n=224
NCT03113448 COMPLETED
0.075% Capsaicin Lotion for the Treatment of Painful Diabetic Neuropathy
Thammasat University n=42
NCT01941329 COMPLETED
Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy.
Association for Innovation and Biomedical Research on Light and Image n=94
NCT01823081 COMPLETED
Combined Intravitreal Fasudil and Bevacizumab for Diabetic Macular Edema
Shahid Beheshti University of Medical Sciences n=74
NCT01973400 COMPLETED
Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus
Universiti Sains Malaysia n=300
NCT01892163 COMPLETED
Multicentre Randomised Clinical Trial Comparing Fixed vs Pro re Nata (PRN) Dosing of 700 μg Dexamethasone
Moorfields Eye Hospital NHS Foundation Trust n=100
NCT01355692 COMPLETED
Evaluation of the Effects of Selective Photocoagulation for the Treatment of Diabetic Macular Edema
Lumenis Be Ltd. n=32
NCT00996437 COMPLETED
Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)
Jaeb Center for Health Research n=261
NCT01323348 COMPLETED
Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control
Jaeb Center for Health Research n=1,875
NCT01813773 COMPLETED
Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy, The A.C.T Study
Ophthalmic Consultants of Long Island n=20
NCT01363440 COMPLETED
Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema
Regeneron Pharmaceuticals n=466
NCT01627977 COMPLETED
Association of Lutein, Zeaxanthin and Brilliant Blue in Chromovitrectomy
Federal University of São Paulo n=18
NCT01726075 COMPLETED
Trial to Assess the Efficacy of Neuroprotective Drugs Administered Topically to Prevent or Arrest Diabetic Retinopathy
BCN Peptides n=450
NCT01748487 COMPLETED
The Effect of Intravitreal Ozurdex on DME After Cataract Surgery
University Health Network, Toronto n=24
NCT01304706 COMPLETED
Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study
Alimera Sciences n=120
NCT00545870 COMPLETED
Bevacizumab Versus Ranibizumab for Diabetic Retinopathy
Ursula Schmidt-Erfurth, M.D. n=30
NCT02308644 COMPLETED
Intravitreous Bevacizumab and Standard Metabolic Control for Diabetic Macular Edema - A Contrast Sensitivity Study
University of Sao Paulo n=41
NCT01135914 COMPLETED
Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)
Novartis Pharmaceuticals n=241
NCT01179672 COMPLETED
A Study in Participants With Diabetic Peripheral Neuropathic Pain in China
Eli Lilly and Company n=405
NCT01171976 COMPLETED
Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus
Novartis Pharmaceuticals n=373
NCT01129960 TERMINATED
Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain
Bial - Portela C S.A. n=332
NCT00853424 WITHDRAWN
A Comparison of Islet Cell Transplantation With Medical Therapy for the Treatment of Diabetic Eye Disease
University of British Columbia
NCT01589718 WITHDRAWN
A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy
Greater Houston Retina Research
NCT01063868 TERMINATED
A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. n=47
NCT01189461 COMPLETED
Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema
Pfizer n=46
NCT00687804 COMPLETED
A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study
Novartis n=345
NCT00997191 COMPLETED
Intravitreal Bevacizumab and Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA)
University of Sao Paulo n=12
NCT00989989 COMPLETED
Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema
Novartis n=396
NCT01131585 TERMINATED
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema
Novartis Pharmaceuticals n=128
NCT00664183 TERMINATED
A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects
Vitreoretinal Technologies, Inc. n=400
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only